Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emily F Higgs

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Science (New York, N.Y.)|August 22, 2020
Immunotherapy with a stingThomas F Gajewski, Emily F Higgs
Biorxiv : the Preprint Server for Biology|April 22, 2024
Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulationEmily F Higgs, Thomas F Gajewski
Journal for Immunotherapy of Cancer|June 15, 2022
Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltrationEmily F Higgs, Riyue Bao, Ken Hatogai, et al.
Journal for Immunotherapy of Cancer|October 1, 2021
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanomaRobin Reschke, Jovian Yu, Blake Flood, et al.
Journal for Immunotherapy of Cancer|October 26, 2024
Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacySantiago Acero-Bedoya, Emily F Higgs, Anna C Martinez, et al.
Immunological Reviews|July 30, 2019
STING pathway agonism as a cancer therapeuticBlake A Flood, Emily F Higgs, Shuyin Li, et al.
Nature Communications|February 1, 2020
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cellsJason B Williams, Shuyin Li, Emily F Higgs, et al.
Biopreservation and Biobanking|June 30, 2022
Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics ToolsEmily F Higgs, Blake A Flood, Athalia R Pyzer, et al.
Cancer Immunology Research|January 14, 2025
PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid CellsKyle R Cron, Ayelet Sivan, Keston Aquino-Michaels, et al.
Cell Reports|April 24, 2024
Batf3<sup>+</sup> DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacyAndrea Ziblat, Brendan L Horton, Emily F Higgs, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Science (New York, N.Y.)|August 22, 2020
Immunotherapy with a stingThomas F Gajewski, Emily F Higgs
Biorxiv : the Preprint Server for Biology|April 22, 2024
Synergistic innate immune activation and anti-tumor immunity through combined STING and TLR4 stimulationEmily F Higgs, Thomas F Gajewski
Journal for Immunotherapy of Cancer|June 15, 2022
Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltrationEmily F Higgs, Riyue Bao, Ken Hatogai, et al.
Journal for Immunotherapy of Cancer|October 1, 2021
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanomaRobin Reschke, Jovian Yu, Blake Flood, et al.
Journal for Immunotherapy of Cancer|October 26, 2024
Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacySantiago Acero-Bedoya, Emily F Higgs, Anna C Martinez, et al.
Immunological Reviews|July 30, 2019
STING pathway agonism as a cancer therapeuticBlake A Flood, Emily F Higgs, Shuyin Li, et al.
Nature Communications|February 1, 2020
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cellsJason B Williams, Shuyin Li, Emily F Higgs, et al.
Biopreservation and Biobanking|June 30, 2022
Insights from a Rapidly Implemented COVID-19 Biobank Using Electronic Consent and Informatics ToolsEmily F Higgs, Blake A Flood, Athalia R Pyzer, et al.
Cancer Immunology Research|January 14, 2025
PKCδ Germline Variants and Genetic Deletion in Mice Augment Antitumor Immunity through Regulation of Myeloid CellsKyle R Cron, Ayelet Sivan, Keston Aquino-Michaels, et al.
Cell Reports|April 24, 2024
Batf3<sup>+</sup> DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacyAndrea Ziblat, Brendan L Horton, Emily F Higgs, et al.
Pageof 2